AIM ImmunoTech (AIM) Receivables - Net (2017 - 2025)

AIM ImmunoTech's (AIM) quarterly Receivables - Net came in at $7000.0 in Q4 2025, down 99.41% on a QoQ basis from $1.2 million in Q4 2023.

AIM ImmunoTech (AIM) Receivables - Net (2017 - 2025) Analysis & Trends

AIM ImmunoTech (AIM) has 8 years of Receivables - Net data on file, last reported at $7000.0 in Q4 2025.

Quarterly Receivables - Net changed N/A year-over-year to $7000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $7000.0 (changed N/A YoY) and the FY2025 annual result came in at $7000.0, changed N/A from the prior year.
Receivables - Net fell to $7000.0 in Q4 2025, from $1.2 million in the prior quarter.
In the past five years, Receivables - Net ranged from a high of $1.8 million in Q1 2023 to a low of $7000.0 in Q4 2025.
A 4-year average of $533444.4 and a median of $34000.0 in 2021 frame the typical range for Receivables - Net.
The widest YoY moves for Receivables - Net: up 7.69% in 2021, down 39.13% in 2021.
Tracing AIM's Receivables - Net over 4 years: stood at $28000.0 in 2021, then surged by 5885.71% to $1.7 million in 2022, then decreased by 29.36% to $1.2 million in 2023, then sank by 99.41% to $7000.0 in 2025.
The last three Receivables - Net figures came in at $7000.0 (Q4 2025), $1.2 million (Q4 2023), and $48000.0 (Q3 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	140.14 Bn	132.29 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	87.02 Bn	79.03 Bn	3.93 Bn
3	Argenx Se	65.30 Bn	60.12 Bn	1.37 Bn
4	Moderna	60.84 Bn	55.70 Bn	52.00 Mn
5	BeOne Medicines	42.15 Bn	37.06 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.49 Bn	28.18 Bn	992.69 Mn
7	BioNTech SE	28.78 Bn	10.38 Bn	668.28 Mn
8	Insmed	27.55 Bn	26.39 Bn	358.27 Mn
9	Royalty Pharma	27.14 Bn	26.31 Bn	-
10	AIM ImmunoTech	4.45 Mn	-5.51 Mn	21,000.00

Download Data